We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for HCA (HCA) Q1 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
Wall Street analysts expect HCA Healthcare (HCA - Free Report) to post quarterly earnings of $5.77 per share in its upcoming report, which indicates a year-over-year increase of 7.7%. Revenues are expected to be $18.31 billion, up 5.6% from the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some HCA metrics that are commonly tracked and projected by analysts on Wall Street.
The combined assessment of analysts suggests that 'Revenue per Equivalent Admission' will likely reach $18,026.95. The estimate is in contrast to the year-ago figure of $17,666.
The collective assessment of analysts points to an estimated 'Equivalent Admissions' of 1.02 billion. Compared to the current estimate, the company reported 981.52 million in the same quarter of the previous year.
The consensus estimate for 'Admissions' stands at 579.28 million. The estimate is in contrast to the year-ago figure of 560.87 million.
Analysts predict that the 'Equivalent Patient Days' will reach 4.96 million. The estimate compares to the year-ago value of 4.87 million.
Based on the collective assessment of analysts, 'Average Length of Stay' should arrive at 5. The estimate compares to the year-ago value of 5.
It is projected by analysts that the 'Number of hospitals' will reach 191. The estimate is in contrast to the year-ago figure of 188.
According to the collective judgment of analysts, 'Inpatient Revenue per Admission' should come in at $19,580.02. Compared to the present estimate, the company reported $18,923 in the same quarter last year.
Analysts' assessment points toward 'Licensed Beds at End of Period' reaching 50,132. Compared to the present estimate, the company reported 49,724 in the same quarter last year.
Analysts expect 'Patient Days' to come in at 2,817.09 Days. Compared to the current estimate, the company reported 2,781.6 Days in the same quarter of the previous year.
The average prediction of analysts places 'Number of freestanding outpatient surgery centers' at 124. Compared to the current estimate, the company reported 121 in the same quarter of the previous year.
Over the past month, HCA shares have recorded returns of -4.9% versus the Zacks S&P 500 composite's -8.9% change. Based on its Zacks Rank #3 (Hold), HCA will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exploring Analyst Estimates for HCA (HCA) Q1 Earnings, Beyond Revenue and EPS
Wall Street analysts expect HCA Healthcare (HCA - Free Report) to post quarterly earnings of $5.77 per share in its upcoming report, which indicates a year-over-year increase of 7.7%. Revenues are expected to be $18.31 billion, up 5.6% from the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some HCA metrics that are commonly tracked and projected by analysts on Wall Street.
The combined assessment of analysts suggests that 'Revenue per Equivalent Admission' will likely reach $18,026.95. The estimate is in contrast to the year-ago figure of $17,666.
The collective assessment of analysts points to an estimated 'Equivalent Admissions' of 1.02 billion. Compared to the current estimate, the company reported 981.52 million in the same quarter of the previous year.
The consensus estimate for 'Admissions' stands at 579.28 million. The estimate is in contrast to the year-ago figure of 560.87 million.
Analysts predict that the 'Equivalent Patient Days' will reach 4.96 million. The estimate compares to the year-ago value of 4.87 million.
Based on the collective assessment of analysts, 'Average Length of Stay' should arrive at 5. The estimate compares to the year-ago value of 5.
It is projected by analysts that the 'Number of hospitals' will reach 191. The estimate is in contrast to the year-ago figure of 188.
According to the collective judgment of analysts, 'Inpatient Revenue per Admission' should come in at $19,580.02. Compared to the present estimate, the company reported $18,923 in the same quarter last year.
Analysts' assessment points toward 'Licensed Beds at End of Period' reaching 50,132. Compared to the present estimate, the company reported 49,724 in the same quarter last year.
Analysts expect 'Patient Days' to come in at 2,817.09 Days. Compared to the current estimate, the company reported 2,781.6 Days in the same quarter of the previous year.
The average prediction of analysts places 'Number of freestanding outpatient surgery centers' at 124. Compared to the current estimate, the company reported 121 in the same quarter of the previous year.
View all Key Company Metrics for HCA here>>>
Over the past month, HCA shares have recorded returns of -4.9% versus the Zacks S&P 500 composite's -8.9% change. Based on its Zacks Rank #3 (Hold), HCA will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>